<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0005110'>Atrial fibrillation</z:hpo>, the commonest <z:hpo ids='HP_0011675'>cardiac arrhythmia</z:hpo>, predisposes to <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> formation and consequently increases risk of ischaemic <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Recent years have seen approval of a number of novel oral <z:chebi fb="2" ids="50249">anticoagulants</z:chebi> </plain></SENT>
<SENT sid="2" pm="."><plain>Nevertheless, <z:chebi fb="8" ids="10033">warfarin</z:chebi> and aspirin remain the mainstays of therapy </plain></SENT>
<SENT sid="3" pm="."><plain>It is widely appreciated that both these agents increase the likelihood of <z:mp ids='MP_0001914'>bleeding</z:mp>: there is a popular conception that this risk is greater with <z:chebi fb="8" ids="10033">warfarin</z:chebi> </plain></SENT>
<SENT sid="4" pm="."><plain>In fact, well-managed <z:chebi fb="8" ids="10033">warfarin</z:chebi> therapy (INR 2-3) has little effect on <z:mp ids='MP_0001914'>bleeding</z:mp> risk and is twice as effective as aspirin at preventing <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>Patients with <z:hpo ids='HP_0005110'>atrial fibrillation</z:hpo> and a further risk factor for <z:hpo ids='HP_0001297'>stroke</z:hpo> (CHA2DS2-VASc &gt;0) should therefore either receive <z:chebi fb="8" ids="10033">warfarin</z:chebi> or a novel oral agent </plain></SENT>
<SENT sid="6" pm="."><plain>The remainder who are at the very lowest risk of <z:hpo ids='HP_0001297'>stroke</z:hpo> are better not prescribed antithrombotic therapy </plain></SENT>
<SENT sid="7" pm="."><plain>For <z:hpo ids='HP_0001297'>stroke</z:hpo> prevention in <z:hpo ids='HP_0005110'>atrial fibrillation</z:hpo>; aspirin is rarely the right choice </plain></SENT>
</text></document>